ESC reports safety of COVID vaccines for patients with cardiovascular disease


COVID-19 vaccination is not associated with an increased risk of heart attack or stroke in patients with cardiovascular disease. The data were obtained from the analysis of patients immunized with BNT162b2 and CoronaVac.

The COVID-19 vaccines BNT162b2 and CoronaVac are not harmful to patients with cardiovascular disease. These are the results of a study published on the website of the European Society of Cardiology (ESC) and in the journal Cardiovascular Research.

The researchers analyzed data from the Hong Kong Hospitals Authority’s electronic health records. Patients with cardiovascular disease from February 23, 2021 to January 31, 2022 were identified.

There was no evidence of an increased risk of cardiovascular events after the first or second dose of the BNT162b2 or CoronaVac vaccines. The results were similar for women and men aged 65 years and older, as well as for patients with various cardiovascular diseases. The results showed the safety of these two vaccines in cardiovascular diseases.

A total of 229,235 patients with cardiovascular disease were identified, of whom 1,764 were vaccinated and had cardiovascular events during the study period (662 received BNT162b2 and 1,102 received CoronaVac). For BNT162b2 and CoronaVac, the researchers estimated incidence ratios to compare the risk of cardiovascular events in the 13 days after vaccination compared with the baseline period. Incidence ratios were also calculated for the risk of complications during the 14 to 27 days after vaccination compared with the baseline period.

Among heart and vascular diseases, coronary heart disease, cerebrovascular diseases, peripheral vascular diseases and stenting were taken into account. Complications include myocardial infarction, stroke, revascularization, and cardiovascular death.

This is the first study to examine the association between COVID-19 vaccines and the risk of complications in patients with heart and vascular disease. Its authors focused on BNT162b2 and CoronaVac, the only COVID-19 vaccines authorized for use in Hong Kong.



Source link